Compare Boston Scientific Corporation (BSX) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs General Motors Company — how do they compare? Boston Scientific Corporation trades at $51.15 (market cap $71.46B), while General Motors Company trades at $89.2 (market cap $76.85B). The key difference: Boston Scientific Corporation and General Motors Company are close in size by market cap, and General Motors Company pays a 0.82% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | GM | |
|---|---|---|
Market Cap | $71.46B | $76.85B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $90.30 |
52-Week Low | $42.63 | $54.16 |
Enterprise Value | $83.55B | $179.83B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
General Motors (GM) trades at $87.58, up 0.74% today, showing strong technical momentum with a bullish moving average signal and support at $87. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.57 beating expectations of $3.19. Recent developments include the renewal of GM's China joint venture with SAIC for 20 years and expansion of EV charging infrastructure with Pilot and EVgo.
GM presents a compelling investment case with analyst consensus price target of $108.82 (24% upside), strong institutional support (65% buy ratings), and improving cash flow trends. However, risks include declining profit margins (1.05% net margin in 2025), rising debt levels, and competitive pressures in the EV transition. The stock offers value with attractive valuation multiples (P/S 0.44, P/B 1.24) but requires monitoring of margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
